Hisamitsu Pharmaceutical Co., Inc. (TYO:4530)

Japan flag Japan · Delayed Price · Currency is JPY
4,290.00
+83.00 (1.97%)
Sep 1, 2025, 3:30 PM JST
1.97%
Market Cap305.82B
Revenue (ttm)154.86B
Net Income (ttm)19.53B
Shares Out71.29M
EPS (ttm)266.77
PE Ratio16.08
Forward PE14.62
Dividend90.00 (2.14%)
Ex-Dividend DateAug 28, 2025
Volume160,000
Average Volume149,635
Open4,220.00
Previous Close4,207.00
Day's Range4,208.00 - 4,319.00
52-Week Range3,783.00 - 4,735.00
Beta0.40
RSI60.32
Earnings DateOct 9, 2025

About TYO:4530

Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals in Japan. The company provides external pain-relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; BUTENALOCK, a remedy for athlete′s foot; and ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP XR, a transdermal analgesic anti-inflammatory drug; and patches for female hormone, asthma, and overactive bladders. The company exports its products to Asia, the United St... [Read more]

Sector Healthcare
Founded 1847
Employees 2,799
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4530
Full Company Profile

Financial Performance

In 2024, TYO:4530's revenue was 156.01 billion, an increase of 10.09% compared to the previous year's 141.71 billion. Earnings were 21.76 billion, an increase of 55.76%.

Financial Statements

News

There is no news available yet.